Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Methodology|Interests|Funding|Corrections
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Consultation record

Submissions not accepted — page 3

The submission is not accepted. The secretariat response gives the reason. A submission that is not accepted remains published in full; the Institute does not remove a submission because it disagrees with it.

Submissions

98 documents · page 3 of 4

Table 1. Submissions with this disposition, on this page.

ReferenceConsultationRespondentPoint raised
DRAFT-LCMSMS-IDENT/005Draft standard CEI-MS-02: Confirmation of peptide identity by liquid…Georgiana ZimmerthalThe document set should be published in translation
DRAFT-PEPTIDE-CONT/008Draft standard CEI-MS-03: Determination of peptide content and its…Dr Rurik Haverkamp-DialloThe document set should be published in translation
DRAFT-WATER-KARL-F/003Draft standard CEI-MS-04: Determination of water content in…Dr Lorcan UttridgeThe standard should require documented operator competence
DRAFT-WATER-KARL-F/014Draft standard CEI-MS-04: Determination of water content in…Dr Xenia Nyquist-ObioraThe standard should state a pass limit
DRAFT-STERILITY-US/001Draft standard CEI-MS-06: Sterility testing of peptide preparations…Dr Xenia Nyquist-ObioraThe standard should state a pass limit
DRAFT-STERILITY-US/007Draft standard CEI-MS-06: Sterility testing of peptide preparations…Dr Zdenka Nyquist-ObioraThe document should state what a reader ought to do
DRAFT-PARTICULATE-/005Draft standard CEI-MS-07: Sub-visible particulate matter in…Dr Jolanta UttridgeThe standard should state a pass limit
DRAFT-PARTICULATE-/009Draft standard CEI-MS-07: Sub-visible particulate matter in…Dr Liesbeth AchterbergThe standard should require documented operator competence
DRAFT-COUNTER-ION-/007Draft standard CEI-MS-10: Identification and quantification of…Dr Zdenka Nyquist-ObioraThe document should state what a reader ought to do
DRAFT-COUNTER-ION-/014Draft standard CEI-MS-10: Identification and quantification of…Dr Liesbeth AchterbergThe standard should require documented operator competence
DRAFT-STABILITY-IN/001Draft standard CEI-MS-13: Development and validation of a…Dr Henrike JastrzębskaThe document should state what a reader ought to do
DRAFT-STABILITY-IN/010Draft standard CEI-MS-13: Development and validation of a…Dr Abimbola Sotomayor-EkwuemeThe standard should state a pass limit
DRAFT-STABILITY-IN/013Draft standard CEI-MS-13: Development and validation of a…Dr Quentin EnthovenThe document set should be published in translation
DRAFT-THIRD-PARTY-/007Draft standard CEI-MS-15: Protocol for independent third-party…Dr Jolanta UttridgeThe standard should state a pass limit
DRAFT-APPEARANCE-S/004Draft standard CEI-MS-09: Assessment of appearance, cake integrity…Dr Jolanta UttridgeThe standard should state a pass limit
DRAFT-APPEARANCE-S/013Draft standard CEI-MS-09: Assessment of appearance, cake integrity…Dr Theodora IngelbrechtThe document should state what a reader ought to do
DRAFT-POORLY-RETAI/007Draft standard CEI-MS-19: Purity determination for peptides not…Dr Theodora TrelawneyThe standard should require documented operator competence
DRAFT-POORLY-RETAI/008Draft standard CEI-MS-19: Purity determination for peptides not…Georgiana ZimmerthalThe document set should be published in translation
DRAFT-PHOTOSTABILI/002Draft standard CEI-MS-20: Photostability assessment of…Dr Zdenka Nyquist-ObioraThe document should state what a reader ought to do
DRAFT-PHOTOSTABILI/003Draft standard CEI-MS-20: Photostability assessment of…Dr Liesbeth Nyquist-ObioraThe standard should state a pass limit
DRAFT-DUAL-VS-SING/003Draft synthesis: Dual and triple incretin receptor agonists compared…Dr Melisande Kirkpatrick-OlaThe review question is drawn too broadly to be answerable
DRAFT-DUAL-VS-SING/004Draft synthesis: Dual and triple incretin receptor agonists compared…Dr Leonhard QuennevilleThe document should state what a reader ought to do
DRAFT-INCRETIN-CAR/005Draft synthesis: Cardiovascular outcomes with glucagon-like peptide-1…Dr Henrike JastrzębskaThe document should state what a reader ought to do
DRAFT-GASTROINTEST/002Draft synthesis: Gastrointestinal adverse events with incretin…Dr Ivo QuintanilhaThe review question is drawn too broadly to be answerable
DRAFT-ORAL-VS-INJE/003Draft synthesis: Oral compared with injectable presentations of…Dr Matthias Wintringham industryThe document should not describe uses outside the approved indication
DRAFT-ORAL-VS-INJE/010Draft synthesis: Oral compared with injectable presentations of…Georgiana ZimmerthalThe document set should be published in translation
DRAFT-SLEEP-APNOEA/015Draft synthesis: Weight-reducing agents for obstructive sleep apnoeaDr Liesbeth Nordhagen industryThe document should not describe uses outside the approved indication
DRAFT-COA-COMPLETE/004Draft synthesis: Completeness of certificates of analysis in the…Dr Perpetua Haverkamp-Diallo industryThe document should not describe uses outside the approved indication
DRAFT-COUNTERION-C/002Draft synthesis: Counter-ion content and its effect on delivered…Dr Matthias Wintringham industryThe document should not describe uses outside the approved indication
DRAFT-GH-SECRETAGO/001Draft synthesis: Clinical evidence for growth-hormone secretagogues…Dr Wolfram Quintanilha industryThe document should not describe uses outside the approved indication

page 3 of 4

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.